BioCentury
ARTICLE | Clinical News

Zealand starts second Phase III of dasiglucagon for severe hypoglycemia

December 15, 2017 8:31 PM UTC

Zealand Pharma A/S (CSE:ZEAL; NASDAQ:ZEAL) began a second Phase III trial to evaluate dasiglucagon delivered in a rescue pen to treat severe hypoglycemia in 156 Type I diabetics. The primary endpoint of the double-blind, placebo-controlled trial is to assess plasma glucose after dasiglucagon treatment. The secondary endpoint will compare glycemic response to marketed reconstituted glucagon in a powder form. Data are expected in 2H18...

BCIQ Company Profiles

Zealand Pharma A/S

BCIQ Target Profiles

Glucagon receptor (GCGR)